Findings

What do systematic reviews say?

3 questions · 3 findings · 1 reviews

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 0 · 0%Low 3 · 100%Moderate 0 · 0%High 0 · 0%

Serious adverse events · non‐hospitalised individuals with COVID‐19

Bamlanivimab showed no clear difference in serious adverse events compared with placebo (low certainty).

1 finding from 1 review

SARS‐CoV‐2‐neutralising monoclonal antibodies for treatment of COVID‐19 2021 · Cochrane Headline outcomes only
RR 0.51 [0.02, 12.47]
1 study · 257 participants
Low

Serious adverse events by day 30 · hospitalised individuals with COVID‐19 (moderate to severe disease)

Bamlanivimab showed no clear difference in serious adverse events by day 30 compared with placebo (low certainty).

1 finding from 1 review

SARS‐CoV‐2‐neutralising monoclonal antibodies for treatment of COVID‐19 2021 · Cochrane Headline outcomes only
RR 0.93 [0.27, 3.14]
1 study · 314 participants
Low

Serious adverse events · non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease)

Bamlanivimab/etesevimab showed no clear difference in serious adverse events compared with placebo (low certainty).

1 finding from 1 review

SARS‐CoV‐2‐neutralising monoclonal antibodies for treatment of COVID‐19 2021 · Cochrane Headline outcomes only
RR 1.4 [0.45, 4.37]
1 study · 1035 participants
Low